Uniqure NV (QURE)

NASDAQ
32.87
-1.63(-4.72%)
After Hours
34.85
+1.98(+6.02%)
- Real-time Data
  • Volume:
    1,032,124
  • Bid/Ask:
    32.26/37.87
  • Day's Range:
    32.78 - 34.93

QURE Overview

Prev. Close
34.5
Day's Range
32.78-34.93
Revenue
37.86M
Open
34.01
52 wk Range
28.58-71.45
EPS
-3.1
Volume
1,032,124
Market Cap
1.51B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
432,105
P/E Ratio
-
Beta
1.22
1-Year Change
-50.78%
Shares Outstanding
45,924,729
Next Earnings Date
Aug 04, 2021
What is your sentiment on Uniqure NV?
or
Market is currently closed. Voting is open during market hours.

Uniqure NV News

Uniqure NV Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Uniqure NV Company Profile

Uniqure NV Company Profile

Employees
332

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Read More
  • 10851397
    0
    • Getting to worthless! Jan, 2017 is the aim?
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.